Cargando…
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
BACKGROUND: Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immunostimulating therapy. In this phase I/IIa study, local AdCD40L immunostimulator...
Autores principales: | Loskog, Angelica, Maleka, Aglaia, Mangsbo, Sara, Svensson, Emma, Lundberg, Christina, Nilsson, Anders, Krause, Johan, Agnarsdóttir, Margrét, Sundin, Anders, Ahlström, Håkan, Tötterman, Thomas H, Ullenhag, Gustav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984796/ https://www.ncbi.nlm.nih.gov/pubmed/27031851 http://dx.doi.org/10.1038/bjc.2016.42 |
Ejemplares similares
-
Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
por: Irenaeus, Sandra, et al.
Publicado: (2017) -
Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
por: Schiza, Aglaia, et al.
Publicado: (2019) -
Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
por: Schiza, A., et al.
Publicado: (2017) -
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
por: Wenthe, Jessica, et al.
Publicado: (2023) -
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
por: Loskog, Angelica
Publicado: (2015)